← Eichor
Study identifier: NCT06456359 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Condition: Desmoplastic Small Round Cell Tumor · Synovial Sarcoma  ·  Sponsor: University Hospital Heidelberg

PhasePhase 2
Planned participants28
Who can joinAll sexes, 13 Years to 50 Years
Healthy volunteersNo

About this study

PAMSARC is a non-commercial interventional Phase 2 clinical trial of academic research institutions, with its primary goal being to improve medical treatment of fusion driven Desmoplastic small round cell tumor (DSRCT) and Synovial sarcoma (SySa) in young adults and adolsecents with male predominance. Current management of DSRCT and SySa includes chemotherapy, radiation and aggressive cytoreductive surgery. Despite advances in multimodal therapy, outcomes remain poor with frequent disease recurrence and very limited options for patients with advanced disease. Selected somatostatin receptor (SSTR) family members, i.e., SSTR2, SSTR3 and SSTR5, are frequently overexpressed in DSRCT and SySa, providing the rationale for treatment with somatostatin analogues (SSA). Pasireotide is a SSA with high affinity for SSTR1, -2, -3, and -5 and is approved for the treatment of Cushing's disease and acromegaly and has also shown activity in other cancers. In patients with advanced stage DSRCT and SySa, conventional chemotherapeutic approaches frequently lead to disease response, however, the duration of progression-free time after chemotherapy is short. The targeted approach with pasireotide after initial intensive multimodal treatment may have the potential to significantly improve outcome.

This description comes directly from the study's public registry record.

Talk to the study team

Richard F. Schlenk, Professor  ·  +49 (0)6221 56 6228  ·  richard.schlenk@nct-heidelberg.de

Editha Gnutzmann, M.A.  ·  +49 6221 36235  ·  e.gnutzmann@nct-heidelberg.de

Always discuss trial participation with your own doctor first.

Locations (4)

National Center for Tumour Diseases, University Hospital HeidelbergHeidelberg, Baden-Wurttemberg, GermanyRecruiting
Klinikum Stuttgart- Olga Hospital Zentrum für Kinder-, Jugend und FrauenmedizinStuttgart, Baden-Wurttemberg, GermanyNot Yet Recruiting
Klinikum Stuttgart Studienzentrale Stuttgart Cancer Center, Tumorzentrum Eva-Mayr-StihlStuttgart, Baden-Wurttemberg, GermanyNot Yet Recruiting
Universitätsklinikum Essen Pädiatrische Hämatologie und OnkologieEssen, North Rhine-Westphalia, GermanyNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06456359